TFG Advisers’s Neurocrine Biosciences NBIX Stock Holding History

TFG Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-50	Closed	-$5K	–	341
2019 Q4	$5K	Buy	+50	New	+$5.24K	﹤0.01%	426

Other funds holding NBIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TFG Advisers's NBIX Position: Q1 2020 in Review

TFG Advisers sold out of Neurocrine Biosciences (NBIX) in Q1 2020, closing a stake of 50 shares — an estimated $5K sold.

TFG Advisers first reported a position in NBIX in Q4 2019 and held it in 1 quarter. The position peaked at $5K in Q4 2019. 368 funds tracked by Wall St. Rank hold NBIX as of Q1 2020.

TFG Advisers reported no remaining Neurocrine Biosciences position as of Q1 2020 after selling out during the quarter.
TFG Advisers sold 50 Neurocrine Biosciences shares in Q1 2020, an estimated $5K.
TFG Advisers first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 1 quarter.
TFG Advisers's Neurocrine Biosciences position peaked at $5K in Q4 2019.
368 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2020.

Based on TFG Advisers's 13F filing for Q1 2020, filed 24 Apr 2020.